Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson’s disease: a bibliometric analysis
Ting Yu, Qingxin Mai, Qian Wang, Mingxia Pan, Yuanfang Xiong, Lingyu Kuang, Hanjiao Liu · 2026
Read Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson’s disease: a bibliometric analysis by Ting Yu, Qingxin Mai, Qian Wang, Mingxia Pan, Yuanfang Xiong, Lingyu Kuang, Hanjiao Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13462061.txt.
Description
Ting Yu and colleagues map, in a 2026 literature analysis, the fast-growing research field linking diabetes-style drugs called GLP-1 receptor agonists to Parkinson's disease. Parkinson's care rests on symptom relief, with no treatment that slows the disease itself. The drugs can reach the brain and, in early studies, calm inflammation, ease cell stress, and improve insulin response. The team searched two databases for work joining the two topics up to April 2026.
282 articles entered the mapping. China led output, followed by the United States and the United Kingdom, with a few universities standing out as hubs. Hot topics included oxidative stress, insulin resistance, the clumping protein alpha-synuclein, the blood-brain barrier, and one drug of the class. Rising themes included mild memory problems and dual-action drugs. The authors say the map shows a field shifting toward multi-target ideas linking body metabolism with brain disease.
Catalog record
| CREATOR | Ting Yu, Qingxin Mai, Qian Wang, Mingxia Pan, Yuanfang Xiong, Lingyu Kuang, Hanjiao Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |